Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Dec 8, 2015
Dividends Not Safe as Energy Markets Swoon
We continue to monitor the carnage in the oil and gas markets, and we encourage readers to evaluate each firm’s unadjusted Dividend Cushion ratio to assess capital-market dependency. For most midstream entities and upstream entities that remain inescapably tied capital cycle builds, the risks are extreme. Dec 7, 2015
Master Limited Partnership Model Still At Risk
The bust may still be ahead of us. Nov 3, 2015
MLPs Breaking Out But More Questions
The data points continue to pile up against the sustainability of this business model… Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer… Oct 27, 2015
A 10%+ Cost of Capital for Midstream Equities Is Reality
Kinder Morgan floated equity capital at a cost of ~12%. The implications are far-reaching. Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead? Oct 25, 2015
Dividend Increases/Decreases for the Week Ending October 23
Let's take a look at companies raising/lowering their dividends this week. Oct 16, 2015
Johnson & Johnson: A Dividend Growth Gem
Johnson & Johnson continues to grow on an operational basis, and its pharmaceutical pipeline may offer huge rewards in coming years. We’re huge fans of its financial profile and lofty dividend coverage. Oct 6, 2015
Transaction Alerts: Moving Closer to Market Neutral on Energy
The absence of energy exposure in the Best Ideas Newsletter portfolio for much of the slide in the price of crude oil has been a tremendous source of upside. The elimination of several profitable positions in the Dividend Growth Newsletter portfolio several months ago has added to significant outperformance there. But now…we’re inching back into energy, if ever so slightly and on a highly diversified basis. Oct 6, 2015
Attention to Pricing Issues Pressures Valeant
Along with the biotech industry as a whole, Valeant Pharmaceuticals has been the subject of negative publicity lately, and its shares have paid the price. The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
